Marvel Biosciences Highlights Recent Research on the Serotonin Theory of Depression
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") highlights recent a meta-analysis which re-evaluated the strength of the link between serotonin levels and depression. According to the study published in Nature Molecular Psychiatry on July 20, 2022 1, despite the influence of the serotonin theory of depression, there was no comprehensive review of the scientific literature undertaken, despite the various known facts of the...
2022-10-04 9:00 AM EDT
Marvel Biosciences Announces Stock Option Grants
Calgary, Alberta--(Newsfile Corp. - September 26, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that its board of directors has approved the grant of incentive stock options (the "Options") to certain directors and officers to acquire an aggregate of 1,425,000 common shares in the capital of the Company at an exercise price of $0.10, which is above the closing price of the...
2022-09-26 4:38 PM EDT
Marvel Biosciences Highlights Recent Research on Link Between NASH and Alzheimer's Disease
Calgary, Alberta--(Newsfile Corp. - August 31, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer's Disease (AD), two programs its lead asset, MB-204 are targeting. A five-year longitudinal study in Sweden tracked subjects with and without NASH over the age of 65, and those with NASH had a 38% higher risk of developing dementia(1). With up to 25% of the population...
2022-08-31 9:00 AM EDT
Marvel Biosciences Closes Second Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its news releases of June 21, 2022 and July 18, 2022, it has closed its non-brokered private placement of 7,200,000 units of the Company (the "Units") at a price of $0.10 per Unit for aggregate gross proceeds of $720,000 (the "Offering"). Each Unit is comprised of...
2022-08-09 9:00 AM EDT
Marvel Announces Identification of a Novel Formulation of Its MB-204 Asset
Calgary, Alberta--(Newsfile Corp. - July 21, 2022) - Marvel Biosciences Inc. (TSXV: MRVL) (the "Company" or "Marvel") is pleased to announce that its rapid formulation screening program with Catalent, Inc., has identified a novel formulation of its lead asset MB-204. The formulation involves producing a solid amorphous dispersion of MB-204 using a simple, FDA approved excipient that has improved drug exposures by at least a factor of 20-fold. Improving oral bioavailability results in reduced...
2022-07-21 4:30 PM EDT
Marvel Biosciences Closes First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - July 18, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its news release of June 21, 2022, it has closed the first tranche of its non-brokered private placement of 4,500,000 units of the Company (the "Units") at a price of $0.10 per Unit for gross proceeds of $450,000 (the "Offering"). Each Unit is comprised of one common...
2022-07-18 9:00 AM EDT
Marvel Biosciences Announces Non-Brokered Private Placement
Calgary, Alberta--(Newsfile Corp. - June 21, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a proposed non-brokered private placement of units (the "Units") at a price of $0.10 per Unit for gross proceeds of up to $700,000 (the "Offering"). Each Unit will be comprised of one common share in the capital of the Company (a "Common Share") and one Common Share purchase...
2022-06-21 9:00 AM EDT
Marvel Biosciences Initiates Formulation Development with Catalent
Calgary, Alberta--(Newsfile Corp. - April 6, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that has initiated its pre-clinical oral formulation studies for its lead compound MB-204 with Catalent, Inc. Catalent, one of the world's largest contract research organizations, has begun development of novel solid amorphous dispersion formulations of MB-204, the Company's novel...
2022-04-06 9:00 AM EDT
Marvel Biosciences Announces Second Quarter 2022 Financial Results
Calgary, Alberta--(Newsfile Corp. - March 30, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") today announced its financial results for the second quarter ended January 31, 2022. For further information on these results, please see the Marvel Biosciences Corp. Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis as filed on SEDAR. "During the quarter ended...
2022-03-30 4:37 PM EDT
Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results
Calgary, Alberta--(Newsfile Corp. - February 16, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report the proxy tabulation ("Tabulation") from Odyssey Trust Company in connection with its Annual and Special Meeting of Shareholders held virtually on February 15, 2022 (the "Meeting"), as well as results from the Meeting. The Tabulation is the final sum of the voting results of the...
2022-02-16 11:48 AM EST
Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results
Calgary, Alberta--(Newsfile Corp. - February 15, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report the proxy tabulation ("Tabulation") from Odyssey Trust Company in connection with its Annual and Special Meeting of Shareholders held virtually on February 15, 2022 (the "Meeting"), as well as results from the Meeting. The Tabulation is the final sum of the voting results of the...
2022-02-15 4:30 PM EST
Marvel Biosciences Provides Corporate Update as it Enters a Significant Value Creating Phase
Calgary, Alberta--(Newsfile Corp. - February 8, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") is pleased to provide a corporate update on the operations of the business. Overview The Company is pursuing a well-known and proven to be effective strategy of redeveloping existing and approved drugs to target new indications and diseases. This is a de-risked approach to drug development, as often,...
2022-02-08 9:00 AM EST
Marvel Biosciences Corp. Announces Change of Chief Financial Officer
Calgary, Alberta--(Newsfile Corp. - February 1, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") is pleased to announce the appointment of Harry Nijjar, CPA, CMA, as Chief Financial Officer of the Company, effective February 1, 2022, replacing Preston Maddin who left the Company effective January 31, 2022. Mr. Nijjar joined Malaspina Consultants Inc. in 2011 and is currently a Managing Director. Malaspina Consultants Inc. has been engaged by the Corporation to provide...
2022-02-01 9:00 AM EST
Marvel Biosciences Completes Manufacturing Engineering Run of Lead Asset MB-204
Calgary, Alberta--(Newsfile Corp. - December 16, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces it has successfully completed a multi-kilogram engineering run of its lead MB-204 asset by Zhejiang Ausun Pharmaceutical Co., Ltd. ("Ausun"). The engineering run material will be used for its ongoing toxicology studies of MB-204 being conducted by Pharmaron Inc. ("Pharmaron"). Pharmaron's...
2021-12-16 9:00 AM EST
Marvel Biosciences Achieves CGMP Milestone and Begins IND-Enabling Pre-Clinical Toxicology Testing of Lead Compound
Calgary, Alberta--(Newsfile Corp. - December 8, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated its pre-clinical investigational new drug ("IND") enabling toxicology studies for its lead compound MB-204 with Pharmaron, Inc. ("Pharmaron"), with its principal office in Louisville, Kentucky. Pharmaron, one of the world's largest contract research...
2021-12-08 9:00 AM EST
Marvel Biosciences to Host Investor Webinar
Calgary, Alberta--(Newsfile Corp. - November 29, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it will host an investor webinar via Zoom on Wednesday, December 1, 2021 at 1:00pm EST. The presentation will feature President and Chief Scientific Officer Mark Williams, who will walk through the investor presentation and provide an update on the business. A question and...
2021-11-29 9:00 AM EST
Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash
Calgary, Alberta--(Newsfile Corp. - November 23, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today announced that it has found its lead asset, MB-204 was active in two different pre-clinical models of non-alcoholic steatohepatitis ("NASH") using fibrosis and the non-alcoholic fatty liver disease activity score (NAS score) endpoints that are analogous to the known approvable NASH endpoints...
2021-11-23 9:00 AM EST
Marvel Biosciences Appoints Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - November 9, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce the creation of its scientific advisory board to help guide the development of its lead asset, MB-204, a fluorinated derivative of the US-FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the...
2021-11-09 8:00 AM EST
Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds
Calgary, Alberta--(Newsfile Corp. - October 27, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that the Company has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or hallucinations that occur with psychedelics which include ketamine, LSD and tryptamine derivatives...
2021-10-27 9:00 AM EDT
Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones
Calgary, Alberta--(Newsfile Corp. - October 15, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that as a result of successful process development of the active pharmaceutical ingredient ("API") of its lead drug MB-204, the Company has now entered an important milestone of engineering and subsequent current good manufacturing practices ("cGMP") run of its multi-kilogram...
2021-10-15 9:00 AM EDT